Gene Delivery in Neuro-Oncology

Karan Singh Dixit*, Priya U Kumthekar

*Corresponding author for this work

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Purpose of Review: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis despite aggressive multimodal management thus novel treatments are urgently needed. Gene therapy is a versatile treatment strategy being investigated in multiple cancers including GBM. In gene therapy, a variety of vectors or “carriers” are used to deliver genes designed for different anti-tumoral effects. Gene delivery vehicles and approaches to treatment will be addressed in this review. Recent Findings: The most commonly studied vectors are viral based, however, driven by advances in biomedical engineering, mesenchymal and neural stem cells, as well as multiple different types of nanoparticles have been developed to improve tumor tropism and also increase gene transfer into tumor cells. Different genes have been studied including suicide genes, which convert non-toxic prodrug into cytotoxic drug; immunomodulatory genes, which stimulate the immune system; and tumor suppressor genes which repair the defect that allow cells to divide unchecked. Summary: Gene therapy may be a promising treatment strategy in neuro-oncology as it is versatile and flexible due to the ability to tailor vectors and genes for specific therapeutic activity. Pre-clinical studies and clinical trials have demonstrated feasibility and safety of gene therapy; however, further studies are required to determine efficacy.

Original languageEnglish (US)
Article number69
JournalCurrent oncology reports
Volume19
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Genetic Therapy
Genes
Glioblastoma
Biomedical Engineering
Therapeutics
Neoplasms
Tropism
Aptitude
Neural Stem Cells
Prodrugs
Tumor Suppressor Genes
Mesenchymal Stromal Cells
Brain Neoplasms
Nanoparticles
Suicide
Immune System
Clinical Trials
Safety
Pharmaceutical Preparations

Keywords

  • Gene therapy
  • Glioblastoma
  • High-grade glioma
  • Nanoparticles
  • Stem cells
  • Viral vectors

ASJC Scopus subject areas

  • Oncology

Cite this

@article{cff9c8025c0645a2be92bc390e67a2df,
title = "Gene Delivery in Neuro-Oncology",
abstract = "Purpose of Review: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis despite aggressive multimodal management thus novel treatments are urgently needed. Gene therapy is a versatile treatment strategy being investigated in multiple cancers including GBM. In gene therapy, a variety of vectors or “carriers” are used to deliver genes designed for different anti-tumoral effects. Gene delivery vehicles and approaches to treatment will be addressed in this review. Recent Findings: The most commonly studied vectors are viral based, however, driven by advances in biomedical engineering, mesenchymal and neural stem cells, as well as multiple different types of nanoparticles have been developed to improve tumor tropism and also increase gene transfer into tumor cells. Different genes have been studied including suicide genes, which convert non-toxic prodrug into cytotoxic drug; immunomodulatory genes, which stimulate the immune system; and tumor suppressor genes which repair the defect that allow cells to divide unchecked. Summary: Gene therapy may be a promising treatment strategy in neuro-oncology as it is versatile and flexible due to the ability to tailor vectors and genes for specific therapeutic activity. Pre-clinical studies and clinical trials have demonstrated feasibility and safety of gene therapy; however, further studies are required to determine efficacy.",
keywords = "Gene therapy, Glioblastoma, High-grade glioma, Nanoparticles, Stem cells, Viral vectors",
author = "Dixit, {Karan Singh} and Kumthekar, {Priya U}",
year = "2017",
month = "11",
day = "1",
doi = "10.1007/s11912-017-0628-z",
language = "English (US)",
volume = "19",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "11",

}

Gene Delivery in Neuro-Oncology. / Dixit, Karan Singh; Kumthekar, Priya U.

In: Current oncology reports, Vol. 19, No. 11, 69, 01.11.2017.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Gene Delivery in Neuro-Oncology

AU - Dixit, Karan Singh

AU - Kumthekar, Priya U

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose of Review: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis despite aggressive multimodal management thus novel treatments are urgently needed. Gene therapy is a versatile treatment strategy being investigated in multiple cancers including GBM. In gene therapy, a variety of vectors or “carriers” are used to deliver genes designed for different anti-tumoral effects. Gene delivery vehicles and approaches to treatment will be addressed in this review. Recent Findings: The most commonly studied vectors are viral based, however, driven by advances in biomedical engineering, mesenchymal and neural stem cells, as well as multiple different types of nanoparticles have been developed to improve tumor tropism and also increase gene transfer into tumor cells. Different genes have been studied including suicide genes, which convert non-toxic prodrug into cytotoxic drug; immunomodulatory genes, which stimulate the immune system; and tumor suppressor genes which repair the defect that allow cells to divide unchecked. Summary: Gene therapy may be a promising treatment strategy in neuro-oncology as it is versatile and flexible due to the ability to tailor vectors and genes for specific therapeutic activity. Pre-clinical studies and clinical trials have demonstrated feasibility and safety of gene therapy; however, further studies are required to determine efficacy.

AB - Purpose of Review: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis despite aggressive multimodal management thus novel treatments are urgently needed. Gene therapy is a versatile treatment strategy being investigated in multiple cancers including GBM. In gene therapy, a variety of vectors or “carriers” are used to deliver genes designed for different anti-tumoral effects. Gene delivery vehicles and approaches to treatment will be addressed in this review. Recent Findings: The most commonly studied vectors are viral based, however, driven by advances in biomedical engineering, mesenchymal and neural stem cells, as well as multiple different types of nanoparticles have been developed to improve tumor tropism and also increase gene transfer into tumor cells. Different genes have been studied including suicide genes, which convert non-toxic prodrug into cytotoxic drug; immunomodulatory genes, which stimulate the immune system; and tumor suppressor genes which repair the defect that allow cells to divide unchecked. Summary: Gene therapy may be a promising treatment strategy in neuro-oncology as it is versatile and flexible due to the ability to tailor vectors and genes for specific therapeutic activity. Pre-clinical studies and clinical trials have demonstrated feasibility and safety of gene therapy; however, further studies are required to determine efficacy.

KW - Gene therapy

KW - Glioblastoma

KW - High-grade glioma

KW - Nanoparticles

KW - Stem cells

KW - Viral vectors

UR - http://www.scopus.com/inward/record.url?scp=85028747776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028747776&partnerID=8YFLogxK

U2 - 10.1007/s11912-017-0628-z

DO - 10.1007/s11912-017-0628-z

M3 - Review article

C2 - 28866732

AN - SCOPUS:85028747776

VL - 19

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 11

M1 - 69

ER -